Axon Reports Significant Momentum Across Federal Sector as U.S. Government Fiscal Year Closes

Awards span across multiple agencies, supporting federal law enforcement, homeland security and veteran healthcare missions

AXON (Nasdaq: AXON), the global public safety technology leader, today announced recent contract awards reflecting the growing adoption of its technology ecosystem across federal agencies.

Axon is the global leader in public safety technology, relentlessly innovating to protect more lives in more places.

From enhancing operational transparency with body-worn cameras to safeguarding VA hospitals, and protecting our nation's airspace, federal entities are leveraging Axon's connected solutions to modernize operations and better serve officers, veterans, and communities nationwide.

Recent Federal Highlights

  • Body-Worn Cameras and Digital Evidence Management: Federal agencies added over 22,000 Axon body-worn cameras and digital evidence management licenses, including translation tools this year.
  • Airspace Security with Counter-Drone Technology: Under an IDIQ contract, the Department of Homeland Security (DHS) chose Axon's Dedrone platform to deliver real-time airspace monitoring, drone identification, and threat mitigation for critical infrastructure protection.
  • TASER Devices for VA Police: The U.S. Department of Veterans Affairs (VA) added over 1,600 TASER 10 devices to begin equipping VA police officers protecting medical centers, veterans and healthcare staff.

For more information: Axon: Secure Solutions for Federal Agencies 

About Axon
AXON (Nasdaq: AXON) is the global leader in public safety technology, relentlessly innovating to protect more lives in more places. Founder-led since 1993, AXON began with a mission to reimagine conflict in law enforcement and has grown into a global company serving everyone who takes on the responsibility of public safety, enterprise security, and national security — from first responders and governments to companies, frontline workers, and communities. Our trusted network connects TASER energy devices, cameras and sensors including body, fixed and in-car cameras, drones and robotics, digital evidence and records management, real-time operations, immersive training, productivity tools, and AI-driven capabilities and insights. Designed to work seamlessly together, these solutions create a connected picture of safety that helps protect people and places with greater speed, clarity, and accountability.

Non-Axon trademarks are the property of their respective owners. Axon, TASER and the Delta Logo are trademarks of Axon Enterprise, Inc., some of which are registered in the US and other countries. For more information, visit www.axon.com/legal. All rights reserved.

Responsible Innovation at Axon
At Axon, innovation is inseparable from responsibility. We believe technology must serve humanity, and every product we build is designed to solve the real challenges our customers face in protecting their communities. That means developing solutions in close collaboration with the people who use them and grounding our work in transparency, fairness, accountability, and privacy. Our independent Ethics & Equity Advisory Council provides ongoing input and feedback that helps shape our approach, ensuring we remain thoughtful and aligned with community needs as technology evolves. Learn more at axon.com/responsibility.

Please visit https://investor.axon.com and https://www.axon.com/newsroom for more information.

Media Contact:
Kate MacKinnon
Vice President, Communications
press@axon.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/axon-reports-significant-momentum-across-federal-sector-as-us-government-fiscal-year-closes-302909135.html

SOURCE Axon

News Provided by PR Newswire via QuoteMedia

AXON
The Conversation (0)

America Can't Make Its Own Ammunition Metal. A Nevada Project Just Defined One of the Largest Domestic Sources

Energy Metal News News Commentary - There is a metal most people have never heard of that the U.S. military cannot do without and cannot currently produce at home. It hardens the lead in ammunition, it is essential to the primers that make bullets fire, and it goes into flame retardants,... Keep Reading...
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies

VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies

CNM-Au8 demonstrated low contrast vision improvement and global neurological improvement (low contrast vision, cognition, upper extremity function, and walking speed) in stable MS patients as adjunct to background immunomodulating disease modifying therapies (DMTs) No approved MS DMTs have shown... Keep Reading...
Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders

Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders

Management, the Board of Directors, and key shareholders represent approximately 11.5 million shares or 46.1% of the issued and outstanding sharesAwakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics... Keep Reading...
Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights

Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, today is reporting its financial results and business highlights for the three and nine months ended... Keep Reading...
Awakn Life Sciences Signs MOU with NHS  and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK

Awakn Life Sciences Signs MOU with NHS and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK

With a Focus on Bringing the KARE Phase II a/b Trial (Ketamine-Assisted Psychotherapy for Alcohol Use Disorder) into Phase IIIAwakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and... Keep Reading...

Interactive Chart

Latest Press Releases

Related News